California State Teachers Retirement System Has $19.07 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

California State Teachers Retirement System cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 0.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 144,731 shares of the company’s stock after selling 920 shares during the period. California State Teachers Retirement System owned about 0.15% of Neurocrine Biosciences worth $19,070,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC raised its position in Neurocrine Biosciences by 66.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock valued at $121,007,000 after acquiring an additional 364,986 shares in the last quarter. Westfield Capital Management Co. LP boosted its holdings in Neurocrine Biosciences by 73.0% in the 3rd quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock valued at $73,045,000 after purchasing an additional 273,952 shares during the period. Norges Bank bought a new position in Neurocrine Biosciences during the fourth quarter valued at about $35,731,000. Jacobs Levy Equity Management Inc. boosted its position in shares of Neurocrine Biosciences by 59.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock valued at $77,892,000 after acquiring an additional 256,920 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Neurocrine Biosciences by 81.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 410,103 shares of the company’s stock worth $54,035,000 after buying an additional 184,660 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 200 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $140.00, for a total transaction of $28,000.00. Following the sale, the insider now directly owns 7,507 shares in the company, valued at $1,050,980. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 200 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $140.00, for a total transaction of $28,000.00. Following the completion of the transaction, the insider now owns 7,507 shares of the company’s stock, valued at approximately $1,050,980. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Eric Benevich sold 75,000 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the completion of the sale, the insider now directly owns 40,778 shares in the company, valued at approximately $5,683,637.64. The disclosure for this sale can be found here. Insiders sold 208,997 shares of company stock valued at $28,773,215 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. BMO Capital Markets raised their price objective on shares of Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a “market perform” rating in a report on Thursday, May 2nd. Evercore ISI initiated coverage on Neurocrine Biosciences in a report on Tuesday, May 14th. They set an “outperform” rating and a $175.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Monday. Finally, Citigroup raised their price target on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $150.85.

Check Out Our Latest Research Report on NBIX

Neurocrine Biosciences Stock Down 0.5 %

Shares of NASDAQ NBIX opened at $133.07 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $92.61 and a twelve month high of $148.37. The stock has a market cap of $13.39 billion, a price-to-earnings ratio of 36.66 and a beta of 0.36. The company’s fifty day moving average is $137.93 and its 200-day moving average is $133.43.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last posted its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.62). The business had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. On average, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Featured Articles

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.